Sign in
PHIO Stock Price, Chart, Stats & News
Phio Pharmaceuticals Corp.
Save
Phio Pharmaceuticals Corp. (PHIO) does not currently pay a dividend.
11.62M
Market cap
–
Current P/E
0.31x
Forward P/E
PHIO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -40.48% |
ROE | -66.59% |
D/E | – |
Interest coverage ratio | – |
PHIO valuation
P/E | – |
P/S | – |
P/B | 0.73x |
P/CF | -1.83x |
P/FCF | -1.83x |
P/OCF | -1.83x |
PEG | -4065.79x |
EV multiple | -3.96x |
About
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Similar securities
Based on sector and market capitalization
Report issue